Investor Kit

Company Profile

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.

Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

Stock Chart

Financials

Date Filing Description Download
12/09/10 8-K Current report filing
12/03/10 4 Statement of Changes in Beneficial Ownership
12/03/10 4 Statement of Changes in Beneficial Ownership
12/03/10 4 Statement of Changes in Beneficial Ownership

Stock Quote

ACOR (Common Stock) $ 21.80 +0.25 (+1.16%) Volume: 685,607 MORE August 17, 2017

Email Alerts

Un-subscribe from email alerts
Email Address *
Mailing Lists *





 
Enter the code shown above.